SYS ONLINE
Supplements/Compound

ASU (Avocado-Soybean Unsaponifiables)

Standardized lipid extract slowing OA progression.

Buy

Overview

Standardized lipid extract slowing OA progression.

Natural sources
  • Endogenously produced or biosynthesized molecule
  • Standardized pharmaceutical- or food-grade supplement
  • Combined with cofactors that improve absorption or activity
Common forms
  • Capsule or softgel
  • Powder
  • Sublingual or buccal
  • Liposomal liquid

Mechanism of action

Inhibits IL-1β, MMPs, and stimulates TGF-β driven cartilage repair.

Pathways
  • · Inhibits IL-1β, MMPs
  • · and stimulates TGF-β driven cartilage repair

Effects on the body

Decreases
NSAID use in hip and knee OA

Organ system effects

Evidence-based benefits

Reduces NSAID use in hip and knee OA

Moderate evidence

Potential side effects

Common
  • · GI upset
Rare
    Serious

      Drug interactions

      Prescription medications (general)
      Always disclose ASU (Avocado-Soybean Unsaponifiables) use to your prescriber — additive, antagonistic, or pharmacokinetic interactions are possible.
      minor

      Supplement interactions

      Pairs well with
      • A high-quality multivitamin
        Covers micronutrient cofactors that support most supplement pathways.
      • Omega-3 (EPA/DHA)
        Foundational anti-inflammatory support that complements most regimens.
      Avoid combining with

      No specific avoidances listed.

      Dosing & bioavailability

      Typical dose
      300 mg/day (Piascledine)
      Best form
      Most evidence is based on the capsule or softgel form.
      Timing
      Consistent daily timing recommended; split larger doses if GI tolerance is a concern.
      With food?
      With food

      Where to buy

      Affiliate links — we may earn a commission at no extra cost to you. Amazon code supplementsch-20 is auto-applied at checkout. We don't endorse specific brands; verify third-party testing (USP, NSF, Informed Sport) before purchase.

      Scientific evidence8Show studies
      RCTArthritis Rheum · 1998

      ASU in hip and knee OA

      Maheu E, et al.

      6-month DB-RCT in 164 hip OA patients.

      Key findings

      Significant reduction in NSAID use vs placebo.

      Open study
      Systematic reviewPubMed (NLM) · 1970

      PubMed: ASU (Avocado-Soybean Unsaponifiables) — Reduces NSAID use in hip and knee OA

      Live PubMed search

      Live results for "ASU (Avocado-Soybean Unsaponifiables) Reduces NSAID use in hip and knee OA" across the PubMed/MEDLINE peer-reviewed index.

      Key findings

      Opens current human and preclinical literature matching ASU (Avocado-Soybean Unsaponifiables) and "Reduces NSAID use in hip and knee OA". Filter by RCT, meta-analysis, or year on the results page.

      Open study
      Systematic reviewPubMed (NLM) · 1970

      PubMed: ASU (Avocado-Soybean Unsaponifiables) — randomized controlled trial

      Live PubMed search

      Live results for "ASU (Avocado-Soybean Unsaponifiables) randomized controlled trial" across the PubMed/MEDLINE peer-reviewed index.

      Key findings

      Opens current human and preclinical literature matching ASU (Avocado-Soybean Unsaponifiables) and "randomized controlled trial". Filter by RCT, meta-analysis, or year on the results page.

      Open study
      Systematic reviewPubMed (NLM) · 1970

      PubMed: ASU (Avocado-Soybean Unsaponifiables) — meta-analysis

      Live PubMed search

      Live results for "ASU (Avocado-Soybean Unsaponifiables) meta-analysis" across the PubMed/MEDLINE peer-reviewed index.

      Key findings

      Opens current human and preclinical literature matching ASU (Avocado-Soybean Unsaponifiables) and "meta-analysis". Filter by RCT, meta-analysis, or year on the results page.

      Open study
      Systematic reviewPubMed (NLM) · 1970

      PubMed: ASU (Avocado-Soybean Unsaponifiables) — pharmacokinetics

      Live PubMed search

      Live results for "ASU (Avocado-Soybean Unsaponifiables) pharmacokinetics" across the PubMed/MEDLINE peer-reviewed index.

      Key findings

      Opens current human and preclinical literature matching ASU (Avocado-Soybean Unsaponifiables) and "pharmacokinetics". Filter by RCT, meta-analysis, or year on the results page.

      Open study
      Systematic reviewPubMed (NLM) · 1970

      PubMed: ASU (Avocado-Soybean Unsaponifiables) — safety adverse events

      Live PubMed search

      Live results for "ASU (Avocado-Soybean Unsaponifiables) safety adverse events" across the PubMed/MEDLINE peer-reviewed index.

      Key findings

      Opens current human and preclinical literature matching ASU (Avocado-Soybean Unsaponifiables) and "safety adverse events". Filter by RCT, meta-analysis, or year on the results page.

      Open study
      Systematic reviewPubMed (NLM) · 1970

      PubMed: ASU (Avocado-Soybean Unsaponifiables) — dose response

      Live PubMed search

      Live results for "ASU (Avocado-Soybean Unsaponifiables) dose response" across the PubMed/MEDLINE peer-reviewed index.

      Key findings

      Opens current human and preclinical literature matching ASU (Avocado-Soybean Unsaponifiables) and "dose response". Filter by RCT, meta-analysis, or year on the results page.

      Open study
      Systematic reviewGoogle Scholar · 1970

      Google Scholar: ASU (Avocado-Soybean Unsaponifiables) — clinical evidence

      Live Scholar search

      Cross-database citation index for ASU (Avocado-Soybean Unsaponifiables) as it relates to "clinical evidence".

      Key findings

      Includes preprints, theses, and journal articles. Useful for tracking citation counts and follow-on work.

      Open study
      Educational use only. This profile is not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you take prescription medication or have a chronic condition.

      Community discussion

      (0 threads)

      Share your experience or read what others have tried. Anecdotes are not medical advice.

      Sign in or create a free account to post or reply.
      Loading discussion…